Abstract
In ulcerative colitis, mucosal healing has clearly been incorporated in the assessment of treatment efficacy. In Crohn’s disease, this concept has only emerged in recent clinical trials with biological therapies. Systemic steroids don’t reliably induce mucosal healing in Crohn’s disease, but purine analogues and anti-TNF agents have a potential to heal mucosal ulcerations. Evidence for mucosal healing has now been provided for the anti-TNF agents infliximab, adalimumab and certolizumab pegol. For infliximab in Crohn’s disease, mucosal healing has been associated with a reduction in clinical relapses, disease-related hospitalizations and surgeries. On the contrary, the benefit of treating asymptomatic patients with IBD more intensively until they achieve mucosal healing has not been proven. In clinical practice, assessing mucosal healing should be considered in patients with persistent symptoms despite adequate therapy as well as in patients where treatment discontinuation is being considered.
Keywords: Crohn’s disease, endoscopy, endpoint, ibd, inflammatory bowel disease, medical therapy, mucosal healing, outcome, ulcerative colitis, anti-TNF agents, endpoint, purine analogues.
Current Drug Targets
Title:Medical Therapy and Mucosal Healing
Volume: 13 Issue: 10
Author(s): Marc Ferrante and Gert Van Assche
Affiliation:
Keywords: Crohn’s disease, endoscopy, endpoint, ibd, inflammatory bowel disease, medical therapy, mucosal healing, outcome, ulcerative colitis, anti-TNF agents, endpoint, purine analogues.
Abstract: In ulcerative colitis, mucosal healing has clearly been incorporated in the assessment of treatment efficacy. In Crohn’s disease, this concept has only emerged in recent clinical trials with biological therapies. Systemic steroids don’t reliably induce mucosal healing in Crohn’s disease, but purine analogues and anti-TNF agents have a potential to heal mucosal ulcerations. Evidence for mucosal healing has now been provided for the anti-TNF agents infliximab, adalimumab and certolizumab pegol. For infliximab in Crohn’s disease, mucosal healing has been associated with a reduction in clinical relapses, disease-related hospitalizations and surgeries. On the contrary, the benefit of treating asymptomatic patients with IBD more intensively until they achieve mucosal healing has not been proven. In clinical practice, assessing mucosal healing should be considered in patients with persistent symptoms despite adequate therapy as well as in patients where treatment discontinuation is being considered.
Export Options
About this article
Cite this article as:
Ferrante Marc and Van Assche Gert, Medical Therapy and Mucosal Healing, Current Drug Targets 2012; 13 (10) . https://dx.doi.org/10.2174/138945012802429679
DOI https://dx.doi.org/10.2174/138945012802429679 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Potential Therapeutic Targets for Steroid-Resistant Asthma
Current Drug Targets The Role of Angiogenesis as a Prognostic Factor of Breast Cancer: Recent Review
Current Women`s Health Reviews Biochemical Properties of Indoleamine 2,3-dioxygenase: From Structure to Optimized Design of Inhibitors
Current Medicinal Chemistry Biological Relevance of Lysophospholipids and Green Solutions for Their Synthesis
Current Organic Chemistry Targeting IL-17 and IL-23 in Immune Mediated Renal Disease
Current Medicinal Chemistry QSPR in Oral Bioavailability: Specificity or Integrality?
Mini-Reviews in Medicinal Chemistry Male Pelvic Pain: Beyond Urology and Chronic Prostatitis
Current Rheumatology Reviews Novel Inhibitors of HIV Discovered Among Existing Classes of Pharmaceutical Compounds Indicated for Unrelated Clinical Indications
Current Pharmaceutical Design New Entrants into Clinical Trials for Targeted Therapy of Breast Cancer: An Insight
Anti-Cancer Agents in Medicinal Chemistry Identification of AHSA1 as a Potential Therapeutic Target for Breast Cancer: Bioinformatics Analysis and <i>in vitro</i> Studies
Current Cancer Drug Targets Cytokines: From Gut Inflammation to Colorectal Cancer
Current Drug Targets Mechanisms of Corticosteroid Resistance in Severe Asthma and Chronic Obstructive Pulmonary Disease (COPD)
Current Pharmaceutical Design Protective Effects of Melatonin and Mitochondria-targeted Antioxidants Against Oxidative Stress: A Review
Current Medicinal Chemistry The Role of Nicotinamide Phosphoribosyltransferase in Cerebral Ischemia
Current Topics in Medicinal Chemistry Patent Selections:
Recent Patents on Food, Nutrition & Agriculture Clinical Pharmacology of Novel Selective COX-2 Inhibitors
Current Pharmaceutical Design Genito-Urological Cancers in Elderly Patients
Anti-Cancer Agents in Medicinal Chemistry A Retrospective Study on <i>Gloriosa superba</i> and Its Main Active Constituents
The Natural Products Journal Cross-Talk between Oxidative Stress and Pro-Inflammatory Cytokines in Acute Pancreatitis: A Key Role for Protein Phosphatases
Current Pharmaceutical Design Peptide Therapeutics and the Pharmaceutical Industry: Barriers Encountered Translating from the Laboratory to Patients
Current Medicinal Chemistry